scholarly journals Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare

2017 ◽  
Vol 2017 ◽  
pp. 1-4
Author(s):  
Terumi Tanigawa ◽  
Shintaro Morisaki ◽  
Hisanobu Fukuda ◽  
Shuichiro Yoshimura ◽  
Hisayoshi Nakajima ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Poor Prognosis ◽  
Lung Metastases ◽  
Careful Consideration ◽  
Subsequent Treatment ◽  
Uterine Leiomyosarcoma ◽  
Therapy Control ◽  
The Poor ◽  
Tumor Enlargement

Pazopanib has activity in patients with soft-tissue sarcoma. We report an advanced uterine leiomyosarcoma case that suddenly worsened after cessation of pazopanib therapy. A 47-year-old woman had a primary uterine leiomyosarcoma tumor and multiple lung metastases, which progressed during her initial treatment. In subsequent treatment with pazopanib for 3 months, the sum of her tumor diameters after cessation sharply increased for two weeks. Symptoms such as dyspnea suddenly worsened also. She died of the disease one month after cessation of pazopanib therapy. Given the poor prognosis of recurrent uterine leiomyosarcoma and the rapid tumor enlargement after ending pazopanib therapy, control of this disease is especially important. Therefore, the decision to discontinue pazopanib therapy requires careful consideration.

Non-surgical Treatments for Lung Metastases in Patients with soft Tissue Sarcoma: Stereotactic Body Radiation Therapy (SBRT) and Radiofrequency Ablation (RFA)

2020 ◽  
Vol 16 ◽  
Author(s):  
Cecilia Tetta ◽  
Maria Carpenzano ◽  
Areej Tawfiq J Algargoush ◽  
Marwah Algargoosh ◽  
Francesco Londero ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Stereotactic Body Radiation Therapy ◽  
Lung Metastases ◽  
Disease Free Interval ◽  
Stereotactic Body Radiation ◽  
Free Interval ◽  
Disease Free

Background: Radio-frequency ablation (RFA) and Stereotactic Body Radiation Therapy (SBRT) are two emerging therapies for lung metastases. Introduction: We performed a literature review to evaluate outcomes and complications of these procedures in patients with lung metastases from soft tissue sarcoma (STS). Method: After selection, seven studies were included for each treatment encompassing a total of 424 patients: 218 in the SBRT group and 206 in the RFA group. Results: The mean age ranged from 47.9 to 64 years in the SBRT group and from 48 to 62.7 years in the RFA group. The most common histologic subtype was, in both groups, leiomyosarcoma. : In the SBRT group, median overall survival ranged from 25.2 to 69 months and median disease-free interval from 8.4 to 45 months. Two out of seven studies reported G3 and one G3 toxicity, respectively. In RFA patients, overall survival ranged from 15 to 50 months. The most frequent complication was pneumothorax. : Local control showed high percentage for both procedures. Conclusion: SBRT is recommended in patients unsuitable to surgery, in synchronous bilateral pulmonary metastases, in case of deep lesions and in patients receiving high-risk systemic therapies. RFA is indicated in case of a long disease-free interval, in oligometastatic disease, when only the lung is involved, in small size lesions far from large vessels. : Further large randomized studies are necessary to establish whether these treatments may also represent a reliable alternative to surgery.

scholarly journals Integrative Clustering Reveals a Novel Subtype of Soft Tissue Sarcoma With Poor Prognosis

2020 ◽  
Vol 11 ◽  
Author(s):  
Zhenhua Zhu ◽  
Zheng Jin ◽  
Haibo Zhang ◽  
Mei Zhang ◽  
Dahui Sun
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Poor Prognosis

scholarly journals Carbonic Anhydrase IX as a Marker for Poor Prognosis in Soft Tissue Sarcoma

2004 ◽  
Vol 10 (13) ◽  
pp. 4464-4471 ◽  
Author(s):  
Kårstein Måseide ◽  
Rita A. Kandel ◽  
Robert S. Bell ◽  
Charles N. Catton ◽  
Brian O’Sullivan ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Carbonic Anhydrase ◽  
Poor Prognosis ◽  
Carbonic Anhydrase Ix

scholarly journals Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis

PLoS ONE ◽  
2010 ◽  
Vol 5 (12) ◽  
pp. e15368 ◽  
Author(s):  
Thomas K. Kilvaer ◽  
Andrej Valkov ◽  
Sveinung Sorbye ◽  
Eivind Smeland ◽  
Roy M. Bremnes ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Poor Prognosis ◽  
Independent Predictor

MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study

2013 ◽  
Vol 13 (1) ◽  
pp. 249-259 ◽  
Author(s):  
J. Martin-Broto ◽  
A. M. Gutierrez ◽  
R. F. Ramos ◽  
J. A. Lopez-Guerrero ◽  
S. Ferrari ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Poor Prognosis

scholarly journals Which Soft Tissue Sarcoma Patients with Lung Metastases Should not Undergo Pulmonary Resection?

Sarcoma ◽  
2002 ◽  
Vol 6 (2) ◽  
pp. 57-60 ◽  
Author(s):  
Albertus N. van Geel ◽  
Joost Rm van Der Sijp ◽  
Paul Im Schmitz
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Pulmonary Resection ◽  
Lung Metastases ◽  
Meta Analysis ◽  
Lung Surgery ◽  
Second Best

Using the second best method of meta-analysis it is significantly shown that patients with an interval of less than 7 months between diagnosis of soft tissue sarcoma and lung surgery for metastases do not benefit.

Sign in / Sign up

Export Citation Format

Share Document